<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135876</url>
  </required_header>
  <id_info>
    <org_study_id>524E-CVD-0056-013</org_study_id>
    <nct_id>NCT00135876</nct_id>
  </id_info>
  <brief_title>Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients</brief_title>
  <official_title>A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH
      (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period,
      for the prevention of VTE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized 1:1 to receive dalteparin 5,000 anti-Xa units s.c. daily versus
      placebo s.c. daily. The primary outcome is VTE-free survival at 6 months. Progression free
      survival; overall survival, toxicity, and neurocognitive performance are secondary outcome
      measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objectively-proven symptomatic VTE (DVT or PE)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding (major and all bleeding)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognition assessments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
  </secondary_outcome>
  <enrollment>512</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Brain Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalteparin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both of the following criteria must be satisfied:

               1. Patients with newly-diagnosed pathologically-confirmed WHO Grade 3 or Grade 4
                  glioma (anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic
                  oligodendroglioma, and anaplastic mixed glioma). Tumour histology is based on
                  local pathology review only;

               2. Patients 18 years of age or older at time of randomization

        Exclusion Criteria:

          -  If one or more of the following criteria are satisfied, the patient is not eligible
             for the study:

               1. The presence of acute or chronic DVT demonstrated by duplex ultrasonography (DUS)
                  or venography. (Note: a screening DUS is not required for study entry);

               2. Inability to commence study drug within four weeks of original surgery or biopsy;

               3. Serious hemorrhage requiring hospitalization, transfusion, or surgical
                  intervention within four weeks of potential study entry;

               4. Presence of a coagulopathy (e.g. INR &gt;1.5 or platelet count &lt; 100x109/L);

               5. Symptomatic intracranial or intratumoural bleeding. (Note: post-operative imaging
                  of the brain is not required for study entry. Asymptomatic “routine”
                  post-operative blood products in a post-surgical cavity are not an exclusion;

               6. Known acute (symptomatic or actively bleeding) gastroduodenal ulcer;

               7. Familial bleeding diathesis;

               8. Requiring long term anticoagulants for other reasons (e.g., mechanical heart
                  valves, atrial fibrillation);

               9. Uncontrolled hypertension despite antihypertensive therapy;

              10. Significant renal failure (dependent on dialysis or creatinine of greater than
                  three times upper limit of normal control);

              11. Prior history of documented DVT or PE;

              12. Allergy to anticoagulants (UFH, LMWH) including immune-mediated heparin-induced
                  thrombocytopenia;

              13. Pregnant or of childbearing potential and not using adequate contraception;

              14. Geographically inaccessible for follow-up;

              15. Having an expected life span of less than 6 months;

              16. Body weight &lt; 40 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Perry, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Geerts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jim Julian, MMath</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Dept of Clinical Epidemiology &amp; Biostatistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kellogg Cancer Center - Evanston Northwestern Healthcare</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The St. George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6847</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto-Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>April 25, 2007</last_update_submitted>
  <last_update_submitted_qc>April 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2007</last_update_posted>
  <keyword>deep vein thrombosis</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>glioma</keyword>
  <keyword>fragmin</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>dalteparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

